It is widely recognized in the field of internal emitter therapy that radiopharmaceuticals are distributed nonuniformly within tissues of localization, and this nonuniformity extends to all spatial levels—organs, suborgans, multicellular clusters, single cells, and even subcellular compartments (1,2). Furthermore, the dosimetric consequences of these distributions have been extensively studied, especially for short-range radiations such as α-particles and Auger electrons (3). Microdosimetric studies that investigate the biologic consequences of internal emitters have explicitly considered nonuniform radioactivity distributions, but in so doing, the See page 1009
radioactivity per labeled cell was considered to be constant (i.e., equal to some mean value) (4,5). Although such studies have given consideration to the fraction of labeled versus unlabeled cells in an organ, tissue, or a cell cluster, the paucity of experimental data on the distribution of activity per cell required the assumption of a constant value per labeled cell in these microdosimetric and cellular-level dosimetry studies.
In June 2006, Neti and Howell published an elegant experimental study that provided data on the distribution of activity per cell (6). Chinese hamster V79 lung fibroblasts were exposed to varying concentrations of 210Po-citrate, and the activity per cell was measured via α-particle autoradiography. Their studies thus gave direct experimental data that cellular uptake in cells is governed by a lognormal distribution and that the shape of that distribution remains unchanged with increases in the distribution mean. Their data was subsequently used to perform theoretic modeling of cell survival as a function of the mean activity per cell. The authors demonstrated substantial differences in cell survival shape when the activity per cell was lognormally distributed versus when it was assumed conventionally that every cell in the population contained the mean activity. This effect was particularly pronounced at cell survival fractions below 10%.
In a subsequent Journal of Nuclear Medicine Letter to the Editor, Kvinnsland et al. (7) suggested that the statistical nature of radioactive decay can influence the measured distribution of α-particle tracks, particularly at low numbers of tracks per cell as studied by Neti and Howell (6). In their response, the authors performed a statistical reanalysis of their original data to further elucidate whether or not Poisson statistics would alter their original conclusions. In an article in this issue of The Journal of Nuclear Medicine, Neti and Howell present an expansion of this reanalysis whereby 3 different distributions are reviewed (Poisson, lognormal, and Poisson-lognormal) to assess the distribution of α-particle tracks per cell measured in their study (8). Their current study showed that at the lower activity concentrations, Poisson statistics do not significantly affect their original conclusions that distributions of lognormal activity concentration are seen in cells exposed to 210Po-citrate, and that at their highest concentration, the Poisson-lognormal distribution perhaps better explains their data.
The statistical arguments put forth by these authors will be valuable to researchers working with cellular uptake models of radiopharmaceuticals as well as those looking at biologic response to internal emitters at the cellular level. Although these in vitro experiments are important sources of data for modeling radiobiologic response to therapy radiopharmaceuticals, the next significant challenge will be to acquire such data within experimental models of tissue structure, within tissues of laboratory animals, and eventually within treated patients in clinical trials. When possible, studies of radioactivity uptake should additionally, and when practical, simultaneously look at the distribution of target cells (if they are not always the same), as both are needed to fully understand biologic outcome (9). Whereas a multitude of factors can influence overall tissue response, ultimately the activity uptake within individual cells of the targeted tissue, as well as uptake within cells of the dose-limiting organ, must be understood to enable the construction of meaningful dose-response relationships, which in turn will eventually lead to improvements in radiopharmaceutical design and targeting strategy.
Footnotes
-
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.
References
- Received for publication March 5, 2008.
- Accepted for publication March 6, 2008.